Added to YB: 2026-09-11
Pitch date: 2026-09-09
KRSA [neutral]
Korsana Biosciences, Inc.
Author Info
No bio for this author
Company Info
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Market Cap
N/A
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
N/A
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Paragon’s new spin is live - Korsana Biosciences
KRSA (update): Korsana is a pre-IND Alzheimer’s platform play whose lead antibody combines a validated plaque target with a blood-brain-barrier shuttle and Fc engineering, aiming for higher brain exposure, lower ARIA and anemia risk, and subcutaneous dosing. At $26.15, the ~$1.44B valuation prices in substantial success, though ~$475M of cash funds operations into 2029. Human safety and penetration data in mid-2027 and interim plaque-clearance data around year-end 2027 are the first major binary events.
Read full article (2 min)